Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers
Sign Up to like & getrecommendations! Published in 2019 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-019-0676-8
Abstract: Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that… read more here.
Keywords: gynecologic cancers; checkpoint inhibitors; immunotherapy checkpoint; checkpoint ... See more keywords
Immunotherapy, checkpoint inhibitor advance to frontline non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Translational cancer research"
DOI: 10.21037/12238
Abstract: For many years, immune-based therapies have been explored in a selected array of cancers traditionally considered “immunogenic”, namely melanoma, prostate, renal cell, non-Hodgkin’s lymphoma, bladder cancer, and renal cell carcinoma. Until recently, lung cancer has… read more here.
Keywords: inhibitor advance; immunotherapy checkpoint; lung cancer; cancer ... See more keywords
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Sign Up to like & getrecommendations! Published in 2020 at "Vaccines"
DOI: 10.3390/vaccines8040578
Abstract: Immune checkpoint inhibitors (ICIs) are beginning to show promise in the clinical management of hepatocellular carcinoma (HCC). Most recently, the anti-programmed death protein-1 (PD-1) agent atezolizumab combined with bevacizumab demonstrated superiority to sorafenib in a… read more here.
Keywords: hepatocellular carcinoma; checkpoint inhibitors; inhibitors hepatocellular; immunotherapy checkpoint ... See more keywords